Parkin Sensitizes toward Apoptosis Induced by Mitochondrial Depolarization through Promoting Degradation of Mcl-1  by Carroll, Richard G. et al.
ArticleParkin Sensitizes toward Apoptosis Induced by
Mitochondrial Depolarization through Promoting
Degradation of Mcl-1Graphical AbstractHighlightsParkin activation can result in mitophagy or apoptosis
Bcl-2 family proteins regulate Parkin-dependent apoptosis
Parkin and PINK1 promote Mcl-1 degradation
Parkin sensitizes toward apoptosis in response tomitochondrial
impairmentCarroll et al., 2014, Cell Reports 9, 1538–1553
November 20, 2014 ª2014 The Authors
http://dx.doi.org/10.1016/j.celrep.2014.10.046Authors
Richard G. Carroll, Emilie Hollville,
Seamus J. Martin
Correspondence
martinsj@tcd.ie
In Brief
Parkin, the ubiquitin ligase that ismutated
in Parkinson’s disease, regulates the
clearance of damaged mitochondria via
selective autophagy (mitophagy). Here,
Carroll et al. show that Parkin activation
in response to mitochondrial impairment
can also result in the elimination of cells
containing depolarized mitochondria via
apoptosis.
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Mitochondrial depolarization promotes Parkin- and
PTEN-induced kinase 1 (PINK1)-dependent poly-
ubiquitination of multiple proteins on mitochondrial
outer membranes, resulting in the removal of defec-
tive mitochondria via mitophagy. Because Parkin
mutations occur in Parkinson’s disease, a condition
associated with the death of dopaminergic neurons
in the midbrain, wild-type Parkin is thought to pro-
mote neuronal survival. However, here we show
that wild-type Parkin greatly sensitized toward
apoptosis induced by mitochondrial depolarization
but not by proapoptotic stimuli that failed to activate
Parkin. Parkin-dependent apoptosis required PINK1
and was efficiently blocked by prosurvival members
of the Bcl-2 family or knockdown of Bax and
Bak. Upon mitochondrial depolarization, the Bcl-2
family member Mcl-1 underwent rapid Parkin- and
PINK1-dependent polyubiquitination and degrada-
tion, which sensitized toward apoptosis via opening
of the Bax/Bak channel. These data suggest that
similar to other sensors of cell stress, such as p53,
Parkin has cytoprotective (mitophagy) or cytotoxic
modes (apoptosis), depending on the degree ofmito-
chondrial damage.INTRODUCTION
Parkin is a ubiquitin E3 ligase that is found in mutant form in
recessive familial Parkinson’s disease, a disorder associated
with loss of dopaminergic neurons in the midbrain (Kitada
et al., 1998; Shimura et al., 2000). PTEN-induced kinase 1
(PINK1), which shuttles between the cytosol and mitochondria,
is also linked with Parkinson’s disease and operates in the
same pathway as Parkin (Valente et al., 2004). Parkin is normally
localized to the cytosol and translocates to depolarized mito-
chondria in a PINK1-dependent manner (Narendra et al., 2008).
In healthy cells, PINK1 is constitutively imported into mitochon-
dria and degraded by mitochondrial proteases but becomes1538 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The Autstabilized on the outer membranes of depolarized mitochondria
and recruits Parkin to mitochondrial outer membranes (Narendra
et al., 2008). Parkin is activated upon PINK1-dependent phos-
phorylation of ubiquitin, which stabilizes the association of Par-
kin on mitochondria and activates its Ub ligase activities (Kane
et al., 2014; Koyano et al., 2014). Upon activation of Parkin,
numerous proteins within the mitochondrial outer membrane
become polyubiquitinated, leading to the recruitment of the
ubiquitin- and LC3-binding adaptor proteins p62 and NBR1 to
mitochondria (Geisler et al., 2010; Narendra et al., 2010). As a
consequence, depolarized mitochondria that are decorated
with p62 and NBR1 become targeted to autophagosomes and
eliminated from the cell via mitophagy (Narendra et al., 2008).
Because Parkinson’s disease is associated with progressive
loss of dopaminergic neurons, it is widely assumed that Parkin
has a cell-death-inhibitory function. However, few studies have
addressed this issue explicitly, and there is a paucity of informa-
tion concerning how Parkin connects to the well-characterized
cell-death machinery. It has been suggested that Parkin blocks
cell death in response to a variety of stimuli (Darios et al., 2003;
MacCormac et al., 2004; Yang et al., 2005; Berger et al., 2009;
Ekholm-Reed et al., 2013; Sun et al., 2013; Wang et al., 2013).
However, many of these studies utilized proapoptotic triggers
(such as etoposide, ceramide, staurosporine, thapsigargin,
death receptor ligands) that do not activate Parkin. Furthermore,
a recent study suggested that Parkin suppresses apoptosis
through promoting NFkB-dependent transcriptional upregu-
lationof themitochondrial innermembraneprotein,Opa1, thereby
antagonizingapoptosis-associatedcytochromec release (Mu¨ller-
Rischart et al., 2013). Furthermore, the latter report also sug-
gested, rather surprisingly, that Parkin inhibits apoptosis in a
PINK1-independent manner (Mu¨ller-Rischart et al., 2013). How-
ever, althoughOpa1hasbeen implicated inapoptosis-associated
cristae junction remodeling, this event is not amajor checkpoint in
apoptosis and overexpression or knockdown of Opa1 does not
greatly alter the threshold for apoptosis (Sheridan et al., 2008).
Instead, it has been well established that members of the Bcl-2
family are the major determinants of cell survival in response to
stresses that impact on the mitochondrial pathway to apoptosis
(Martin et al., 2012). Thus, how Parkin influences cell-death deci-
sions requires further clarification.
Here, we have explored the role of Parkin as a regulator of
apoptosis in response to mitochondrial depolarizing agents,hors
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which are well established to promote Parkin activation during
mitophagy (Narendra et al., 2008; Vives-Bauza et al., 2010;
Van Humbeeck et al., 2011). In sharp contrast to the claims
that Parkin suppresses apoptosis, here we report that Parkin
dramatically sensitized cells toward apoptosis induced by mito-
chondrial depolarization-inducing agents, whereas mutant Par-
kin failed to do so. Moreover, under the same conditions, Parkin
had no discernable effect on apoptosis induced by a range of
other proapoptotic stimuli that failed to activate this E3 ligase.
Parkin-dependent apoptosis was associated with PINK1/Par-
kin-dependent degradation of Mcl-1 and overexpression of the
latter, as well as other prosurvival Bcl-2 family proteins, sup-
pressed Parkin-dependent cell death. These data challenge
the view that Parkin is invariably an inhibitor of apoptosis
and suggest, instead, that its role may be to facilitate the repair
(via mitophagy) or elimination (via apoptosis) of cells carrying
impaired or dysfunctional mitochondrial networks. Thus, similar
to the DNA damage sensor p53, which promotes either DNA
repair or apoptosis in response to genomic damage, Parkin acti-
vation may have two distinct outcomes (mitophagy or apoptosis)
depending on the degree of mitochondrial impairment. The
failure of Parkin-dependent mitophagy and/or apoptosis may
therefore permit the accumulation of cells carrying defective
mitochondrial networks.
RESULTS
Parkin and PINK1 Promote Ubiquitination and Removal
of Depolarized Mitochondria
To explore the role of Parkin as a regulator of cell death, we
initially confirmed that wild-type Parkin could promote mitoph-
agy in response to mitochondrial depolarization. HeLa cells
lack detectable Parkin but express endogenous PINK1 and
exhibit robust mitophagic clearance of mitochondria upon
expression of Parkin in these cells (Hollville et al., 2014). As
previously reported by several laboratories, depolarization of
mitochondria using the protonophore CCCP led to rapid translo-
cation of transfected Parkin from the cytosol to mitochondria
within a few hours of CCCP treatment (Figure 1A). Coincident
with Parkin translocation, mitochondrial networks in CCCP-
treated cells collapsed around the perinuclear region, as re-
vealed by TOM20 staining (Figure 1A). Parkin translocation to
mitochondria was followed, within 24 hr, by complete loss of
multiple mitochondrial markers, such as TOM20, HSP60, and
cytochrome c (Figures 1B, S1A, and S1B). Consistent with pre-
vious results (Narendra et al., 2008, 2010; Vives-Bauza et al.,Figure 1. Parkin Promotes Removal of Depolarized Mitochondria but
Stimuli
(A) HeLa cells were transfected with a plasmid encoding mCherry-Parkin (400 n
immunostained for TOM20 (green), and nuclei were stained with Hoechst (blue).
(B) HeLa cells were transfected and treated as in (A). Mitochondria were immunost
or cytochrome c-negative cells were counted among mCherry-Parkin-positive c
(C andD) HeLa cells were transfectedwith a plasmid encoding eGFP (50 ng) along
with anti-Fas (200 ng/ml), TRAIL (100 ng/ml), cisplatin (50 mM), etoposide (100 mM
death was quantified in GFP-positive cells based on cell morphology by phase a
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s-t test. Asterisk(s) indic
1540 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The Aut2010; Matsuda et al., 2010; Geisler et al., 2010), depolarized
mitochondria in Parkin-expressing cells became heavily deco-
rated with ubiquitin and the ubiquitin-binding adaptor protein
p62 (Figures S1C and S1D). GFP-LC3 also relocalized to depo-
larizedmitochondria within Parkin-transfected cells (Figure S1E).
Thus, mitochondrial depolarization in HeLa cells promoted rapid
recruitment of Parkin to these organelles, followed by ubiquitina-
tion of mitochondrial substrates, decoration of depolarized mito-
chondrial networks with the ubiquitin-binding proteins p62 and
LC3, culminating in the elimination of these organelles via
mitophagy.
Parkin Fails to Suppress Apoptosis in Response to
Diverse Proapoptotic Stimuli
HeLa cells are sensitive to numerous proapoptotic stimuli,
including those that engage the extrinsic death receptor
pathway (Fas, TRAIL, TNF) as well as the intrinsic or mitochon-
drial pathway (cytotoxic drugs, DNA damage as well as many
other stimuli) to apoptosis (Cullen et al., 2013). To explore
whether Parkin suppressed apoptosis routed through either
the extrinsic or intrinsic pathways, we transfected cells with
either empty vector, or a cDNA encoding wild-type Parkin,
along with a GFP expression plasmid to mark transfected cells.
As a positive control, we used the well-characterized antiapop-
totic protein, Bcl-xL, which blocks apoptosis induced by
numerous stimuli (Sheridan et al., 2008). After 24 hr, cells
were then treated with a diverse panel of proapoptotic stimuli.
However, as shown in Figures 1C and 1D, Parkin failed to pro-
vide any protection toward apoptosis induced by Fas, TRAIL,
cisplatin, etoposide, daunorubicin, or actinomycin D. In sharp
contrast, Bcl-xL exhibited robust antiapoptotic effect toward
all of the proapoptotic stimuli used (Figures 1C and 1D). Surpris-
ingly, however, expression of Parkin dramatically sensitized to-
ward apoptosis induced by the mitochondrial depolarizer CCCP
(Figures 1C and 1D).
Parkin Selectively Sensitizes toward Mitochondrial
Depolarization-Initiated Apoptosis
To ask whether the increased sensitivity toward mitochondrial
depolarization-induced apoptosis was reproducible in other
cell types, we repeated the preceding experiments in two
additional cell lines. As illustrated in Figures 2A and 2B, Parkin
failed to exhibit any antiapoptotic activity toward a diverse
panel of extrinsic or intrinsic proapoptotic stimuli in either
MCF-7 or SH-SY5Y cells. However, once again, there was a
clear sensitization toward apoptosis induced by mitochondrialFails to Suppress Apoptosis in Response to Diverse Proapoptotic
g) for 24 hr and treated with CCCP (10 mM) for 6 or 24 hr. Mitochondria were
Cells were analyzed by confocal microscopy. Scale bars represent 20 mm.
ained for TOM20, HSP60, or cytochrome c. TOM20-negative, HSP60-negative,
ells.
with the indicated amount of Parkin or Bcl-XL cDNA for 24 hr. Cells were treated
), daunorubicin (5 mM), actinomycin D (5 mM), or CCCP (10 mM) for 18 hr. Cell
nd fluorescence microscopy (C), and images were acquired (D).
ror bars indicate SD of triplicate counts of a minimum of 100 cells. Statistical
ate significance, *p% 0.01, **p% 0.001, ***p% 0.0001. See also Figure S1.
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depolarization (CCCP) in both cell lines (Figures 2A and 2B).
Of the cells that failed to die after exposure to mitochondrial de-
polarization agents after 24 hr, the majority of these displayed
features of mitophagy (Figures S2A and S2B). However, the sur-
viving cell population also underwent apoptosis after prolonged
(48–72 hr) exposure to CCCP or valinomycin (Figure S2A).
Of note, the sensitizing effects of Parkin toward mitochondrial
depolarization-induced apoptosis were highly selective and
were not observed in response to any of the other proapoptotic
stimuli used (Figures 1C, 2A, and 2B). Furthermore, the proapo-
ptotic effects of Parkin were readily observed over a wide range
of CCCP concentrations (Figures 2C and S2B), as well as a range
of Parkin plasmid concentrations (Figure 2D). We also explored
whether apoptosis induced by other mitochondrial depolarizing
agents was also enhanced in the presence of Parkin. As can
be seen from Figures 2E and S2B, Parkin also greatly increased
sensitivity toward apoptosis induced by valinomycin, as well as
the combination of oligomycin and antimycin A (Figure 2F). It is
noteworthy that the only stimuli that elicited Parkin-dependent
increases in apoptosis share in common the ability to trigger Par-
kin activation and PINK1 stabilization (Figure 2G, left panel), as
well as Parkin translocation to mitochondria (Figures S2C–
S2G). In contrast, treatment with Fas, TRAIL, cisplatin, daunoru-
bicin, etoposide, or actinomycin D failed to activate Parkin or
stabilize PINK1 (Figure 2G, right panel). Thus, expression of Par-
kin sensitized three independent cell lines toward apoptosis
induced by mitochondrial depolarization, but not other proapo-
ptotic stimuli.
Parkin-dependent cell death in response to mitochondrial de-
polarization exhibited stereotypical features of apoptosis, such
as chromatin condensation and nuclear fragmentation (Fig-
ure 2H), was accompanied by mitochondrial cytochrome c
release (Figures 2I, S2H, and S2I), activation of multiple proapo-Figure 2. Parkin Enhances Mitochondrial Depolarization-Initiated Apo
(A and B) MCF-7 (A) and SH-SY5Y (B) were transfected with a plasmid encoding e
Cells were treatedwith anti-Fas (200 ng/ml), TRAIL (100 ng/ml), cisplatin (50 mM), d
for 24 hr. Cell death was counted among GFP-positive cells based on cell morph
(C) HeLa cells were transfected as in (A) andwere then treatedwith the indicated do
morphology.
(D) HeLa cells were transfected with a plasmid encoding eGFP (50 ng) along with
CCCP (10 mM) for 24 hr, and cell death was counted among GFP-positive cells b
(E and F) HeLa cells were transfected with a plasmid encoding eGFP (50 ng) alo
valinomycin (E) or with the indicated dose of oligomycin and antimycin A (500 nM
morphology.
(G) HeLa-YFP-Parkin cells were treated with CCCP (10 mM), valinomycin (50 nM),
Fas (200 ng/ml), TRAIL (100 ng/ml), cisplatin (50 mM), daunorubicin (5 mM), etopo
PINK1 stabilization and Parkin activation was analyzed by western blotting.
(H) HeLa-YFP-Parkin cells were treated with CCCP (10 mM) in the presence or ab
blue), and nuclear fragmentation was imaged by phase and fluorescence micros
(I) HeLa-YFP-Parkin cells were treated with CCCP (10 mM) for the indicated perio
analyzed by western blotting.
(J) HeLa-YFP-Parkin cells were treated with the indicated dose of CCCP or vali
western blotting.
(K) HeLa-YFP-Parkin cells were treated with CCCP (10 mM), valinomycin (50 nM),
DNA content was analyzed by flow cytometry.
(L and M) HeLa-YFP-Parkin cells were treated with the indicated dose of CCCP or
(10 mM) for 14 (L) or 20 hr (M). Cell death was scored based on cell morphology
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s-t test. Asterisk(s) indic
1542 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The Autptotic caspases and proteolysis of caspase substrates (Fig-
ure 2J), as well as DNA fragmentation (Figure 2K). Furthermore,
Parkin-dependent apoptosis induced by mitochondrial depolar-
ization was readily attenuated with the polycaspase inhibitor
Q-VD (Figures 2H, 2K–2M, S2J, and S2K).
Collectively, these data demonstrate that not only did Parkin
fail to protect against apoptosis initiated by multiple proapo-
ptotic stimuli, but this E3 ligase greatly sensitized toward mito-
chondrial-depolarization-induced apoptosis, a condition that
activates Parkin.
Mitochondrial Depolarization-Induced Apoptosis Is
Enhanced by Parkin in a PINK1-Dependent Manner
PINK1 is stabilized on mitochondrial outer membranes in
response to mitochondrial depolarization (Vives-Bauza et al.,
2010; Figure 3A). However, PINK1 stabilization, on its own,
was not sufficient to sensitize toward apoptosis induced by
CCCP (Figures 3A and 3B). The latter result strongly suggests
that apoptosis in this context is Parkin-dependent and that accu-
mulation of PINK1 on the mitochondrial outer membrane is
insufficient.
To explore whether Parkin-dependent apoptosis required
PINK1, we used small interfering RNA (siRNA)-mediated knock-
down of the latter. As shown in Figure 3C, PINK1 was very effi-
ciently silenced using specific siRNAs, and this completely
blocked the translocation of Parkin to mitochondria in response
toCCCP treatment, as expected.We then explored the effects of
PINK1 knockdown on mitochondrial depolarization-induced
apoptosis and, as can be seen from Figure 3D, silencing of
PINK1 expression reversed the Parkin-dependent sensitization
to apoptosis seen in response to CCCP or valinomycin treat-
ment. Thus, mitochondrial depolarization-induced apoptosis re-
quires both Parkin and PINK1, with neither alone being sufficient.ptosis
GFP (50 ng) along with the indicated amount of Parkin or Bcl-XL cDNA for 24 hr.
aunorubicin (5 mM), etoposide (100 mM), actinomycin D (5 mM), or CCCP (10 mM)
ology.
se of CCCP for 18 hr. Cell deathwas scored in GFP-positive cells based on cell
the indicated amount of Parkin cDNA for 24 hr. Cells were treated or not with
ased on cell morphology.
ng with Parkin cDNA for 24 hr. Cells were treated with the indicated dose of
) (F) for 18 hr. Cell death was counted among GFP-positive cells based on cell
or antimycin A (500 nM) + oligomycin (100 nM) for 18 hr (left panel) or with anti-
side (100 mM), antinomycin D (5 mM), or CCCP (10 mM) for 12 hr (right panel).
sence of Q-VD-OPh (10 mM) for 14 hr. Nuclei were stained with Hoechst (2 mM,
copy. Scale bars represent 20 mm.
d of time before mitochondrial and cytoplasmic fractions were prepared and
nomycin for 24 hr. Caspases and caspase substrates were then analyzed by
orcisplatin (50 mM) in the presence or absence of Q-VD-OPh (10 mM) for 20 hr.
valinomycin or with cisplatin (50 mM) in the presence or absence of Q-VD-OPh
(L), and DNA content of cells was analyzed by flow cytometry (M).
ror bars indicate SD of triplicate counts of a minimum of 100 cells. Statistical
ate significance, *p% 0.01, **p% 0.001, ***p% 0.0001. See also Figure S2.
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PINK1-Induced Parkin Translocation to Mitochondria
Selectively Enhances Apoptosis Induced by
Mitochondrial Depolarization
Parkin is constitutively cytosolic and inactive in the absence
of mitochondrial depolarization (Figures 1A and 2G). Thus, the
failure of Parkin to modulate apoptosis induced by cytotoxic
stimuli other than mitochondrial depolarizers may be related to
its inactive (cytosolic) state, as mitochondrial depolarizers were
the only proapoptotic stimuli capable of activating Parkin and
promoting its translocation to mitochondria (Figures 2G and
S2C–S2G). Although Parkin activation is typically achieved
through mitochondrial depolarization, which stabilizes PINK1
on mitochondrial outer membranes, this can also be achieved
through overexpression of PINK1, which is sufficient to trigger
Parkin translocation to mitochondria (Figure 3E). Thus, we next
explored whether PINK1 overexpression-mediated activation
of Parkin could modulate apoptosis induced by diverse proapo-
ptotic stimuli. Despite being activated and relocalized to mito-
chondria through overexpression of PINK1 (Figure 3E), Parkin
failed to block or enhance apoptosis induced by death recep-
tor ligands such as Fas, TRAIL, or apoptosis induced by cyto-
toxic drugs (Figure 3F). Once again, CCCP-induced apoptosis
was dramatically enhanced in the presence of Parkin/PINK1
(Figure 3F).
PINK1-Mediated Parkin Activation Is Sufficient to
Promote Apoptosis in the Absence of Mitochondrial
Depolarization
Because PINK1 overexpression was sufficient to promote Parkin
activation and translocation to mitochondria, even under condi-
tions where mitochondria remained polarized (Figure 3E), we
wondered whether Parkin activation in the absence of mitochon-
drial depolarization was sufficient to promote apoptosis. Coex-
pression of Parkin in the presence or absence of PINK1 over
a range of concentrations revealed that the combination ofFigure 3. Mitochondrial Depolarization-Induced Apoptosis Is Enhance
(A) HeLa cells were cotransfected with a plasmid encoding eGFP (50 ng) and eit
treated with the indicated dose of CCCP for 18 hr. PINK1 stabilization was analy
positive cells based on cell morphology by phase and fluorescence microscopy
(B) HeLa cells were transfected with a plasmid encoding mCherry-Parkin (400
immunostained for TOM20 (green) and nuclei were stained with Hoechst (blue). C
20 mm.
(C) HeLa cells were transfected with nontargeting control siRNA or siRNA targete
mCherry-Parkin (200 ng) and incubated for a further 24 hr before treatment with C
(top left panel). Cells were also immunostained for mitochondria (TOM20, green),
Parkin and mitochondria was quantified by confocal microscopy among mCherry
(D) HeLa cells were transfected with nontargeting control siRNA, siRNA targete
control (scrambled) or against Bax or Bak (500 ng) for 24 hr. Cells were then transf
Knockdown efficiency was analyzed by western blotting (left panel). Cells were tr
scored based on cell morphology.
(E) HeLa cells were transfected with a plasmid encoding mCherry-Parkin (200
immunostained for PINK1 (green) or ubiquitin and mitochondria (TOM20, blue).
ubiquitin (bottom right panel) was analyzed and scored by confocal microscopy.
(F) HeLa cells were transfectedwith plasmids encoding eGFP (50 ng) and PINK1 (1
treatedwith cisplatin (50 mM), anti-Fas (200 ng/ml), TRAIL (100 ng/ml), daunorubici
cells based on cell morphology.
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s-t test. Asterisk(s) indic
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MCF-7, HEK293T, and SH-SY5Y cells (Figures 4A–4C). PINK1/
Parkin-dependent cell death was readily inhibited using the pol-
ycaspase inhibitor Q-VD (Figure S3A) and exhibited stereotypical
features of apoptosis such as chromatin compaction and exten-
sive plasma membrane blebbing (Figures 3C and S3B), as well
as caspase activation (Figure S3C), caspase substrate proteoly-
sis (Figure S3C), and DNA fragmentation (Figures S3D and S3E).
We also explored whether the Ub ligase activity of Parkin was
required for CCCP-induced apoptosis by using two different
Parkin mutants (Figure 4D), one of which (ParkinC431F) failed
to translocate to depolarized mitochondria, whereas the
ParkinR275W mutant did so but failed to promote mitochondrial
ubiquitination (Figures S3F–S3I). As illustrated in Figure 4E,
both Parkin mutants were impaired in sensitizing toward CCCP
or valinomycin-induced apoptosis, despite being as efficiently
expressed as wild-type Parkin (Figure S3G).
Silencing of Endogenous Parkin or PINK1 Protects
against Apoptosis Induced by Mitochondrial
Depolarization but Not Other Stimuli
Because the experiments described thus far used Parkin overex-
pression approaches, we next asked whether endogenous Par-
kin was required for mitochondrial depolarization-induced
apoptosis. SH-SY5Y cells naturally express Parkin and PINK1
(Figure 4F) and are susceptible to apoptosis induced by mito-
chondrial depolarization (Figure 4G). However, upon knockdown
of endogenous Parkin or PINK1, SH-SY5Y cells were protected
against CCCP- and valinomycin-induced apoptosis, but not
apoptosis induced by cisplatin (Figure 4G). Similarly, HEK293T
cells were also protected against mitochondrial depolarization-
associated apoptosis through knockdown of endogenous Parkin
or PINK1 (Figure 4H). These data provide further support for the
idea that Parkin and PINK1 can promote apoptosis in response
to acute mitochondrial depolarization.d by Parkin in a PINK1-Dependent Manner
her empty vector (200 ng) or Parkin vector (200 ng) for 24 hr. Cells were then
zed by western blotting (left panel), and cell death was counted among GFP-
(right panel).
ng) for 24 hr and treated with CCCP (10 mM) for 12 hr. Mitochondria were
ell morphology was assessed by confocal microscopy. Scale bars represent
d against PINK1 for 24 hr. Cells were then transfected with a plasmid encoding
CCP (10 mM) for 6 hr. Knockdown efficiency was analyzed by western blotting
and nuclei were stained with Hoechst (blue). Colocalization between mCherry-
-Parkin-positive cells (top right and bottom panel). Scale bars represent 20 mm.
d against PINK1, or plasmids encoding GFP-tagged shRNA targeted against
ected with a plasmid encoding Parkin (200 ng) and incubated for a further 24 hr.
eated with CCCP (10 mM) or valinomycin (50 nM) for 24 hr, and cell death was
ng) along with the indicated amount of PINK1 cDNA for 24 hr. Cells were
Colocalization between mitochondria and mCherry-Parkin (top right panel) or
Scale bars represent 20 mm.
00 ng) alongwith the indicated amount of Parkin cDNA for 24 hr. Cells were then
n (5 mM), or CCCP (10 mM) for 18 hr. Cell death was scored amongGFP-positive
ror bars indicate SD of triplicate counts of a minimum of 100 cells. Statistical
ate significance, *p% 0.01, **p% 0.001, ***p% 0.0001.
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Parkin-Dependent Apoptosis Is Blocked by Bcl-2 Family
Members and Is Associated with Enhanced Bax
Activation
Two major pathways to apoptosis have been identified, one of
which (the intrinsic pathway) promotes caspase activation and
apoptosis through permeabilization of mitochondrial outer
membranes via activation of the Bax/Bak channel (reviewed in
Martin et al., 2012). Opening of the Bax/Bak channel is posi-
tively regulated by BH3-only members of the Bcl-2 family and
suppressed by prosurvival Bcl-2 family members, such as
Bcl-xL, Mcl-1, and Bcl-2 (Willis et al., 2007). Of note, we have
recently reported that translocation of Parkin to mitochondria
in response to mitochondrial depolarization is impaired through
overexpression of members of the prosurvival subset of the Bcl-
2 family, thereby inhibiting mitophagy downstream (Hollville
et al., 2014). Thus, we wondered whether Parkin-dependent
apoptosis could also be inhibited by prosurvival Bcl-2 family
proteins.
To explore this, we coexpressed Parkin in the presence or
absence of Bcl-xL, Bcl-2, Mcl-1, Bcl-B, or A1, followed by
exposure of cells to CCCP or valinomycin. As can be seen
from Figures 5A and 5B, Bcl-2 family proteins robustly pro-
tected from Parkin-dependent apoptosis, suggesting that Par-
kin activates the intrinsic pathway to apoptosis. Because the
intrinsic pathway promotes activation of the Bax/Bak channel
to facilitate cytochrome c release, we next explored whether
Parkin led to enhanced Bax activation in response to mitochon-
drial depolarizing agents. Thus, we stained CCCP-treated Par-
kin-transfected HeLa cells with an antibody (6A7) specific for
the active form of Bax. As Figures 5C and 5D illustrate, Parkin
greatly sensitized toward Bax activation in response to mito-
chondrial depolarization. To explore further the role of the
Bax/Bak channel in Parkin-dependent apoptosis, we silenced
the expression of endogenous Bax, Bak, or both, followed by
exposure to CCCP or valinomycin. As Figure 5E shows, knock-
down of Bax or Bak, or both, robustly protected from Parkin/
PINK1-dependent apoptosis in response to mitochondrial
depolarization.Figure 4. PINK1-Mediated Parkin Activation Is Sufficient to Promote A
(A) HeLa, MCF-7, HEK293T, and SH-SY5Y cells were transfected with plasmids
PINK1 cDNA for 24 or 48 hr. Cell death was counted among GFP-positive cells b
(B) HeLa, MCF-7, HEK293T, and SH-SY5Y cells were transfected with plasmids
Parkin cDNA for 24 or 48 hr. Cell death was counted among GFP-positive cells b
(C) HeLa cells were transfected with a plasmid encoding mCherry-Parkin (400 ng)
for TOM20 (green), and nuclei were stained with Hoechst (blue). Cell morphology
(D) Diagram representing the location of point mutations associated with Parkins
(E) HeLa cells were transfected with a plasmid encoding eGFP (50 ng) along with P
24 hr. Cells were treated with the indicated dose of CCCP or valinomycin for 18 hr
(F) SH-SY5Y cells were transfected with nontargeting control siRNA, siRNA target
PINK1 for 48 hr. Knockdown efficiency was analyzed by western blotting.
(G) SH-SY5Y cells were transfectedwith nontargeting control siRNA, siRNA target
PINK1 for 48 hr. Cells were then treated with CCCP (20 mM) or valinomycin (200 n
morphology.
(H) HEK293T cells were transfected with nontargeting control siRNA, siRNA target
PINK1 for 48 hr. Cells were then treated with CCCP (10 mM) or valinomycin (50 n
morphology.
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s-t test. Asterisk(s) indic
1546 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The AutParkin and PINK1 Promote Selective Degradation of
Mcl-1 in Response to Mitochondrial Depolarization
Because prosurvival members of the Bcl-2 family are localized to
mitochondrial outer membranes and set a threshold for Bax/Bak
activation, we considered the possibility that active Parkin might
promote degradation of one ormore Bcl-2 family proteins to pro-
mote opening of the Bax/Bak channel, leading to apoptosis.
Therefore, we monitored the stability of the major prosurvival
Bcl-2 family proteins expressed in HeLa cells (Mcl-1, Bcl-xL,
Bcl-2, and Bcl-W) in response to mitochondrial depolarization.
As Figure 5F shows, Mcl-1 was selectively and rapidly degraded
upon CCCP treatment, in tandem with Parkin activation and
PINK1 stabilization, whereas the stability of other prosurvival
Bcl-2 family members was largely unaffected under the same
conditions.Moreover, knockdown of PINK1 completely reversed
CCCP-induced degradation of Mcl-1 and blocked the activation
of Parkin (Figure 5F). Furthermore, addition of the proteasome in-
hibitor MG132 blocked the degradation of Mcl-1 seen upon
treatment with CCCP (Figure 5G). We also explored the fate of
Bax and Bak in response tomitochondrial depolarization. As Fig-
ure 5H illustrates, whereas Bax expression levels remained sta-
ble in response to mitochondrial depolarization, Bak was also
degraded in tandem with Mcl-1. However, the decline in Bak
expression levels appeared to be a consequence of caspase
activation, because this effect was reversed with the polycas-
pase inhibitor zVAD-fmk, whereas Mcl-1 degradation was only
minimally affected under the same conditions (Figure 5H).
Collectively, these data suggested that in response to mito-
chondrial depolarization, Parkin/PINK1 promote the selective
degradation of the prosurvival Bcl-2 family memberMcl-1, which
may explain the increased sensitivity of Parkin-expressing cells
to apoptosis.
Parkin and PINK1 Promote Polyubiquitination and
Degradation of Mcl-1
The preceding results suggested that activated Parkin promotes
Mcl-1 degradation in response to mitochondrial depolarization.
To explore this further, we looked for evidence of Mcl-1poptosis in the Absence of Mitochondrial Depolarization
encoding eGFP (50 ng) and Parkin (200 ng) along with the indicated amount of
ased on cell morphology.
encoding eGFP (50 ng) and PINK1 (200 ng) along with the indicated amount of
ased on cell morphology.
along with PINK1 vector (200 ng) for 24 hr. Mitochondria were immunostained
was assessed by confocal microscopy. Scale bars represent 20 mm.
on’s disease in the Parkin gene (PARK2).
arkin wild-type (WT), Parkin R275W, Parkin C431F, or Bcl-XL cDNA (200 ng) for
. Cell death was counted among GFP-positive cells based on cell morphology.
ed against an irrelevant protein (TMEM16F), or siRNA targeted against Parkin or
ed against an irrelevant protein (TMEM16F), or siRNA targeted against Parkin or
M) for 36 hr or cisplatin (50 mM) for 20 hr. Cell death was scored based on cell
ed against an irrelevant protein (TMEM16F), or siRNA targeted against Parkin or
M) for 36 hr or cisplatin (50 mM) for 20 hr. Cell death was scored based on cell
ror bars indicate SD of triplicate counts of a minimum of 100 cells. Statistical
ate significance, *p% 0.01, **p% 0.001, ***p% 0.0001. See also Figure S3.
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ubiquitination upon CCCP treatment. As Figures 6A and 6B
demonstrate, in response to mitochondrial depolarization in
HeLa cells stably expressing Parkin, we detected high-molecu-
lar-weight forms of Mcl-1, consistent with ubiquitination of
the latter, which were enhanced through addition of the protea-
some inhibitor, MG132. Mitochondrial depolarization-induced
appearance of Mcl-1 high-molecular-weight species was greatly
attenuated through knockdown of PINK1, which blocked activa-
tion of Parkin (Figure 6C), suggesting that Parkin may promote
polyubiquitination and degradation of Mcl-1 upon mitochondrial
depolarization. To explore this further, we transfected Parkin-ex-
pressing HeLa cells with His-tagged ubiquitin and pulled down
ubiquitin conjugates in the presence and absence of CCCP to
explore whether Mcl-1 was polyubiquitinated under the latter
conditions. As Figure 6D demonstrates, ubiquitin adducts of
Mcl-1 were readily detected in response to mitochondrial depo-
larization-induced Parkin activation. In addition, knockdown of
PINK1 attenuated polyubiquitination of Mcl-1 in response to
mitochondrial depolarization (Figure 6E).
We also asked whether transient expression of Parkin could
promote Mcl-1 degradation. As Figure 6F illustrates, coexpres-
sion of Mcl-1 with Parkin led to a dramatic reduction in Mcl-
1 expression levels, which was greatly enhanced through addi-
tion of CCCP. Furthermore, Parkin overexpression also led to
the detection of Mcl-1 high-molecular-weight species upon
CCCP treatment, consistent with ubiquitination of the latter (Fig-
ures 6G and 6H), and pull-down of ubiquitin conjugates in the
presence of Parkin revealed that Mcl-1 ubiquitination was
enhanced in the presence of this E3 ligase upon CCCP treatment
(Figure 6I).
Collectively, these results strongly suggest that Mcl-1 is a
direct substrate for Parkin-mediated polyubiquitination and
degradation in response to mitochondrial depolarization.
Knockdown of Mcl-1 Sensitizes toward Mitochondrial
Depolarization-Induced Apoptosis
Because the preceding results suggested that Mcl-1 underwent
selective Parkin/PINK1-dependent degradation in response toFigure 5. Parkin/PINK1-Induced Cell Death Is Regulated by Bcl-2 Fam
(A) HeLa cells were cotransfected with plasmids encoding eGFP (50 ng) and Par
(600 ng) for 24 hr. Cells were treated with CCCP (10 mM) or valinomycin (50 nM)
morphology.
(B) HeLa cells were transfected as in (A). Cells were then treated with CCCP (5 mM
positive cells based on cell morphology.
(C and D) HeLa cells were cotransfected with plasmids encoding eGFP (50 ng) a
CCCP or with cisplatin (50 mM) for 18 hr. Cells were immunostained for the active f
analyzed by confocal microscopy, and GFP-positive cells were scored for 6A7 p
(E) HeLa cells were transfected with plasmids encoding GFP-tagged shRNA targ
targeted against PINK1 for 24 hr. Cells were then transfected with Parkin cDNA (
valinomycin (50 nM), cisplatin (50 mM), daunorubicin (5 mM), or actinomycin D (5
morphology.
(F) HeLa-YFP-Parkin cells were transfected with nontargeting control siRNA or siR
(10 mM) for the indicated period of time. Bcl-2 family proteins expression was an
(G) HeLa-YFP-Parkin cells were treated with the indicated dose of CCCP in the pr
was analyzed by western blotting.
(H) HeLa-YFP-Parkin cells were treated with CCCP (10 mM) in the presence or abs
expression was analyzed by western blotting.
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s t test. Asterisk(s) indic
1548 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The Autmitochondrial depolarization, we wondered whether knockdown
of Mcl-1 was sufficient to sensitize toward mitochondrial depo-
larization-induced apoptosis. As controls, we also knocked
down othermembers of the prosurvival subset of the Bcl-2 family
(Bcl-2, Bcl-B, and Bcl-W). As Figure 7A shows, knockdown of
Mcl-1 in Parkin-expressing HeLa cells greatly sensitized toward
apoptosis induced by mitochondrial depolarizing agents. In
contrast, knockdown of Bcl-2, Bcl-B, and Bcl-W had much
more modest effects by comparison (Figure 7A). Similarly,
knockdown of Mcl-1 in SH-SY5Y cells also greatly sensitized
toward apoptosis induced by mitochondrial depolarization
(Figure 7B).
Altogether, these data suggest that Parkin activation in
response to mitochondrial depolarization sensitizes toward
apoptosis through lowering the threshold for opening of the
mitochondrial Bax/Bak channel, at least in part through degrada-
tion of the prosurvival Bcl-2 family member Mcl-1.
DISCUSSION
Here, we have shown that, rather surprisingly, Parkin sensitized
toward apoptosis induced by mitochondrial depolarization. This
effect was highly selective and was not observed in response to
a range of additional proapoptotic stimuli that failed to activate
Parkin, including initiators of the extrinsic pathway to apoptosis
(Fas, TRAIL), as well as initiators of the intrinsic pathway
(cisplatin, etoposide, daunorubicin, actinomycin D). Interest-
ingly, Parkin mutants recapitulating the mutations found in Par-
kinson’s disease were greatly impaired in their ability to sensitize
toward apoptosis. Parkin-dependent apoptosis was PINK1-
dependent and was associated with activation of the Bax/Bak
channel. Furthermore, mitochondrial depolarization triggered
rapid and selective polyubiquitination and degradation of the
prosurvival Bcl-2 family protein Mcl-1, which was blocked
through inhibition of Parkin activation via knockdown of PINK1.
These observations suggest, somewhat heretically, that Parkin
may be a proapoptotic protein that polices mitochondrial integ-
rity and is capable of either initiating repair of mitochondrialily Proteins
kin (200 ng) along with plasmids encoding the indicated Bcl-2 family member
for 24 hr, and cell death was scored among GFP-positive cells based on cell
) or valinomycin (50 nM) for 24, 48, or 72 hr. Cell death was scored among GFP-
nd Parkin (400 ng) for 24 hr. Cells were then treated with the indicated dose of
orm of Bax (anti-Bax 6A7, red) and stained for nuclei (Hoechst, blue). Cells were
ositivity. Scale bars represent 20 mm.
eted against control (scrambled) or against Bax or Bak (500 ng) or with siRNA
200 ng) and incubated for a further 24 hr before treatment with CCCP (10 mM),
mM) for 18 hr. Cell death was scored among GFP-positive cells based on cell
NA targeted against PINK1 (siRNA #2) for 48 hr. Cells were treated with CCCP
alyzed by western blotting.
esence or absence of MG132 (10 mM) for 1 hr. Bcl-2 family proteins expression
ence of zVAD-fmk (10 mM) for the indicated period of time. Bcl-2 family protein
ror bars indicate SD of triplicate counts of a minimum of 100 cells. Statistical
ate significance, *p% 0.01, **p% 0.001, ***p% 0.0001.
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networks via mitophagy or promoting the elimination of critically
damaged cells via apoptosis.
Although it is frequently assumed that Parkin is a suppressor
of apoptosis, few studies have explored the mechanistic basis
for the apparent cytoprotective activity of this ubiquitin ligase
(Darios et al., 2003; MacCormac et al., 2004; Yang et al.,
2005; Berger et al., 2009; Ekholm-Reed et al., 2013; Sun
et al., 2013; Wang et al., 2013). Johnson and colleagues have
reported that Parkin-mediated ubiquitination of Bax provides a
protective effect against etoposide (Johnson et al., 2012). How-
ever, as we have shown here, etoposide failed to activate Par-
kin. Mu¨ller-Rischart et al. (2013) also reported that induction
of OPA1 expression by Parkin mediates Parkin antiapoptotic
function in response to staurosporine. However, it is relevant
to note that none of these studies demonstrated that Parkin
ubiquitin ligase activity was stimulated under the conditions
used. In agreement with established models of mitophagy (Nar-
endra et al., 2008), we have found that PINK1-mediated activa-
tion of the ubiquitin ligase activity of Parkin is absolutely
required for the proapoptotic function of the latter. Therefore,
although the idea that Parkin can suppress apoptosis would
apparently correlate with the loss of dopaminergic neurons in
Parkinson’s disease, there is very little mechanistic evidence
to support this model. An alternative model is that the Parkin-
dependent removal of cells carrying defective mitochondria
may enable the early replacement of dysfunctional neurons,
thereby preventing their accumulation. The latter effect may
be critical to prevent neural networks becoming populated
with defective neurons that might lead to neurodegeneration
upon reaching a tipping point where large numbers of dysfunc-
tional cells die en mass. Pruning of individual neurons, in a Par-
kin-dependent manner, as mitochondrial defects are detected
may enable the efficient replacement of defective neurons,
thereby preventing the accumulation of large numbers of injured
cells and the loss of a whole network.
Although the data reported here would appear contradictory
to the currently proposed models, Parkin proapoptotic activity
has been sporadically noted (Lee et al., 2012; Morrison et al.,
2011). Moreover, Mcl-1 was recently described as a substrate
for Parkin in response to mitochondrial depolarizers (Sarraf(B) HeLa-YFP-Parkin cells were treated with CCCP (10 mM) for the indicated perio
analyzed by western blotting.
(C) HeLa-YFP-Parkin cells were transfected with nontargeting control siRNA or siR
(10 mM) in the presence or absence of MG132 (10 mM) for 1 hr. Mcl-1 expression
(D) HeLa-YFP-Parkin cells were transfected with a plasmid encoding His-tagge
presence or absence of MG132 (10 mM) for 1 hr. His-tagged ubiquitin was then p
(E) HeLa-YFP-Parkin cells were transfected with nontargeting control siRNA or s
with a plasmid encoding His-tagged ubiquitin and incubated for a further 24 hr.
(10 mM) for 1 hr. His-tagged ubiquitin was pulled down, and Mcl-1 ubiquitination
(F) HeLa cells were transfected with a plasmid encoding FLAG-Mcl-1 (200 ng) an
with CCCP (10 mM) for 4 hr. Mcl-1 expression was analyzed by western blotting.
(G) HEK293T cells were transfected with the indicated amount of YFP-Parkin plas
MG132 (10 mM) for 1.5 hr. Mcl-1 expression was analyzed by western blotting.
(H) HEK293T cells were transfected with the indicated amount of YFP-Parkin WT
(10 mM) in the presence or absence of CCCP (10 mM) for 2 hr. Mcl-1 expression
(I) HEK293T cells were transfected with the indicated amount of YFP-Parkin plas
MG132 (10 mM) in the presence or absence of CCCP (10 mM) for 2 hr. His-tagged
blotting.
Results shown are representative of at least three independent experiments.
1550 Cell Reports 9, 1538–1553, November 20, 2014 ª2014 The Autet al., 2013). Furthermore, a very recent study also provides ev-
idence to support the idea that Parkin and PINK1 can collaborate
to promote apoptosis (Zhang et al., 2014). The latter study, which
utilizes Parkin- or PINK1-null mouse embryonic fibroblasts, com-
plements the findings of the present study very well and sug-
gests that deregulated Parkin activation, in response to severe
mitochondrial depolarization, can result in cell death (Zhang
et al., 2014).
We have recently shown that members of the prosurvival
subset of the Bcl-2 family can regulate the onset of Parkin-
dependent mitochondrial clearance through suppressing Parkin
translocation to depolarized mitochondria (Hollville et al., 2014).
Here, we show that prosurvival members of the Bcl-2 family also
suppress Parkin-dependent apoptosis through antagonizing
Parkin function. Thus, there is a reciprocal interplay between
Parkin and Bcl-2 family members that sets a threshold for Par-
kin-dependent mitophagy, or Parkin-dependent apoptosis.
Parkin may act as a sensor for mitochondrial damage or
dysfunction, becoming recruited to damaged mitochondria to
promote their removal via mitophagy, or if mitochondrial impair-
ment is extensive, to promote death of the injured cell via
apoptosis. The functional outcome of Parkin activation may be
dose dependent, with mitophagy occurring at low thresholds
of Parkin activation and apoptosis at higher levels. Limited or
transient mitochondrial depolarization may engage Parkin-
dependent mitophagy, leading to mitochondrial network repair
and cell survival. However, robust or sustained activation of Par-
kin may lead to the opposite outcome of apoptosis to facilitate
removal of the damaged cell. This is reminiscent of how many
biological sensors operate. For example, the tumor suppressor
protein, p53, is involved in monitoring DNA integrity and is acti-
vated in response to DNA damage, thereby promoting DNA
repair (Kastan et al., 1991). However, in response to extensive
DNA damage, p53 activation promotes the elimination of cells
via apoptosis (Lowe et al., 1993). Recent studies suggest that
this effect is related to the degree of DNA damage that promotes
p53 activation, with low levels of damage triggering the repair
function of p53 and higher levels of damage unleashing its pro-
apoptotic activity (Purvis et al., 2012; Chen et al., 2013). Similarly,
Myc activation can lead to cell proliferation or apoptosisd of time in the presence or absence of MG132 (10 mM). Mcl-1 expression was
NA targeted against PINK1 (siRNA #1) for 48 hr. Cells were treated with CCCP
was analyzed by western blotting.
d ubiquitin (5 mg) for 24 hr. Cells were then treated with CCCP (10 mM) in the
ulled down, and Mcl-1 ubiquitination was analyzed by western blotting.
iRNA targeted against PINK1 (siRNA #1) for 24 hr. Cells were then transfected
Cells were treated with CCCP (10 mM) in the presence or absence of MG132
was analyzed by western blotting.
d the indicated amount of YFP-Parkin cDNA for 24 hr. Cells were then treated
mid. Cells were then treated with CCCP (10 mM) in the presence or absence of
or YFP-Parkin C431F construct for 24 hr. Cells were then treated with MG132
was analyzed by western blotting.
mid along with His-tagged ubiquitin cDNA (2 mg). Cells were then treated with
ubiquitin was pulled down, and Mcl-1 ubiquitination was analyzed by western
hors
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depending on the context and Ras activation can promote cell
division, cell senescence, or cell death (Evan et al., 1992;
Serrano et al., 1997; Elgendy et al., 2011).
In conclusion, here we have shown that Parkin selectively
promotes apoptosis in response to mitochondrial depolariza-
tion in a PINK1-dependent manner. These data challenge the
view that Parkin is an inhibitor of apoptosis and suggest,
instead, that its role may be to facilitate the elimination of
cells carrying large numbers of impaired or dysfunctional
mitochondria.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa cells, HeLa cells stably expressing YFP-Parkin, and MCF-7 were
cultured in RPMI supplemented with 5% fetal calf serum (Sigma-Aldrich)
and L-glutamine (Gibco). HEK293T cells were cultured in Dulbecco’sminimum
essential medium supplemented with 10% fetal calf serum. SH-SY5Y were
cultured in Dulbecco’s minimum essential medium supplemented with 15%
fetal calf serum, L-Glutamine, nonessential amino acids, and sodium pyruvate.
Cells were maintained in 5% CO2 at 37
C.
Tranfections and Gene Silencing
HeLa, MCF-7, and SH-SY5Y cells were seeded at 105 cells/well in 6-well
plates 24 hr prior to transfection. Cells were transfected with Genejuice (Merck
Millipore) for 24 hr. HEK293T cells were seeded at 105 cells/well in 6-well plates
24 hr prior transfection and were transfected according to the standard cal-
cium phosphate precipitation method. For siRNA transfections, HeLa and
HeLa-YFP-Parkin cells (6–10 3 105) were nucleofected with 200 pmol of
each siRNA in nucleofection buffer (5 mM KCl, 15 mM MgCl2, 20 mM HEPES,
150 mM Na2HPO4 [pH 7.2]) using Amaxa Nucleofector (program I-013). Cells
(2 3 105 cells/well) were plated in 6-well plates. SH-SY5Y cells were seeded
at 5 3 104 cells/well in 6-well plates 24 hr prior transfection with 200 nM of
siRNA using Lipofectamine 2000 (Invitrogen, Life Technologies). HEK293T
were seeded at 105 cells/well in 6-well plates 24 hr prior transfection with
200 pmol of siRNA according to the standard calcium phosphate precipitation
method.
Western Blot Analysis
Whole-cell lysates were prepared with 100 ml of SDS-PAGE sample buffer on
ice. Samples were boiled for 10 min, ran on 10% or 12% SDS-PAGE gels, and
transferred onto nitrocellulose membranes. After blocking and incubation with
primary and secondary antibodies, immunoreactions were visualized with
SuperSignal West Pico (Thermo Scientific) and exposure to autoradiography
films.
Sub-G1 Analysis
HeLa-YFP-Parkin cells were seeded at 105 cells/well in 6-well plates 48 hr prior
treatment. Cells were fixed with 1ml ice-cold 70% ethanol overnight at20C.
Fixed cells were pelleted at 750 g for 5 min and incubated in 1 ml of PBS for
30 min at room temperature. Cells were pelleted 750 g for 5 min and incubated
in 500 ml of PBS containing 100 mg/ml RNase A for 30min at room temperature.
Cells were stained with 50 mg/ml PI before analysis with BD Biosciences
FACSCalibur.Figure 7. Knockdown of Mcl-1 Sensitizes toward Mitochondrial Depol
(A) HeLa-YFP-Parkin cells were transfected with nontargeting control siRNA or siR
efficiency was analyzed by western blotting (top left panel). Cells were treated wit
for 12 hr or with oligomycin (500 nM) and antimycin A (500 nM) for 14 hr. Cell de
(B) SH-SY5Y cells were transfected with nontargeting control siRNA or siRNA targ
was analyzed by western blotting (top left panel). Cells were treated with daunoru
Cell death was scored based on cell morphology.
Results shown are representative of at least three independent experiments. Er
significance was assessed by two-tailed paired Student’s t test. Asterisk(s) indic
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